All In Biotech

Drug Trial Radar · NCT06516289

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib/ HRS-1167, Famitinib and Camrelizumab: A Prospective, Open-label, Multicenter, Phase II Trial

Last checked: Nov 20, 2026Latest source record: Dec 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Sep 30, 2024

Primary completion

Jun 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, open-label, multi-center, phase II clinical trial designed for HER2-negative breast cancer with pathogenic mutations in the germline gene (gBRCA1/2) that were indicated for neoadjuvant chemotherapy. The characteristics of this study are a precision treatment scheme without chemotherapy, the scheme of HRS-1167 combined with famitinib neoadjuvant therapy for patients with gBRCA mutations is explored, and the efficacy of combined immunotherapy is further explored according to the efficacy of the combination of the two drugs.

Conditions

  • BRCA-Mutated Breast Carcinoma
  • HER2-negative Breast Cancer

Interventions

  • HRS-1167Drug

    a highly selective PARP1 inhibitor

  • FamitinibDrug

    a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit

  • CamrelizumabDrug

    a humanised anti-programmed death-1 (anti PD-1) antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety run-in: Incidence rate of dose-limiting toxicities (DLTs)Time frame: 28±3 days
  2. Safety run-in: adverse events (AEs)Time frame: 28±3 days
  3. Safety run-in: Serious adverse events (SAEs)Time frame: 28±3 days
  4. Phase 2: Total Pathologic complete response (tpCR: ypT0/Tis ypN0) rateTime frame: Immediately after the surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Breast cancer institute of Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.